Bad News for BMS Drug Opdivo Which Falters During Late Stage Lung Cancer Study

Oct 14, 2018 | Bristol-Meyers Squibb, Oncology, Small Cell Lung Cancer

Investment publication Seeking Alpha, reports that Bristol-Myers Squibb’s Opdivo (nivolumab) failed to meet primary end point. The American-based global pharmaceutical company was evaluating Opdivo vs. standard of care (topotecan or amrubicin) in patients with relapsed small cell lung cancer. See the article for more details.

0 Comments

Pin It on Pinterest